“Greatness is not a function of circumstance. Greatness, it turns out, is largely a matter of conscious choice, and discipline.” ― James C. Collins, Good to Great: Why Some Companies Make the Leap… and Others Don’t
Good to Great was published back in 2001; however, I believe the quote above still serves as an overall guide for marketing organizations’ need to create innovation in
So, where are we now?
I recently have spoken with a few industry leaders at pharmaceutical industry conferences and inevitably they ask “Neil, how can I re-organize the way we do business to maximize my Multichannel and content marketing strategy?” This conversation inevitably leads to a series of
I recently watched a profile on 60 Minutes that profiled the author Alison Levine which motivated me to blog on some important insights into leadership. In case you don’t know her, Alison is the author of the New York Times best-selling book, “On The Edge”. The Edge reflects on the lessons learned from
A lot has been written about how social media is misunderstood, particularly in regards to determining ROI for this very important media marketing device. Notice I didn’t say, “channel”. The mistake that is being made is that individuals and companies are thinking of social media as a channel. Social media is a system not a simple marketing channel such as direct mail or print media. Systems thinking is
ESC 2020 – Jardiance joins Farxiga in showing heart failure benefit https://www.evaluate.com/vantage/articles/events/conferences/esc-2020-jardiance-joins-farxiga-showing-heart-failure-benefit
Nestlé agrees $2.6bn deal for Aimmune Therapeutics https://www.ft.com/content/355c51ae-650f-4ee3-8742-bfd3fef0dbc2?segmentid=acee4131-99c2-09d3-a635-873e61754ec6
Why Novavax's Coronavirus Vaccine Might Be First to Market @themotleyfool #stocks $NVAX $PFE $JNJ $AZN $MRNA https://www.fool.com/investing/2020/08/28/why-novavaxs-coronavirus-vaccine-might-be-first-to/
Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH - https://endpts.com/takeda-inks-up-to-500m-extra-cellular-matrix-biotech-for-nash/
